Study #2020-0862
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
tucatinib, trastuzumab deruxtecan
Description
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HER2 Positive Breast Cancer
Study phase:
Phase II
Physician name:
Rashmi Murthy
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-888-836-9251
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.